Axion BioSystems, a specialist in advanced live-cell analysis technology, has launched Synexus, a next-generation platform for disease research and therapeutic development.
Synexus provides richer, more connected views of cell behaviour, redefining how researchers investigate dynamic biological systems.
Synexus unites function and morphology on the same plate, bringing single-cell resolution to high-throughput, label-free workflows. Combining proven microelectrode array (MEA) technology, next-generation high-density MEA (HD-MEA), and electrical imaging, its range of measurement modes lets scientists choose the capabilities best suited to each experiment, creating a platform that adapts as research evolves.
Julien Bradley, CEO of Axion BioSystems, said, “Synexus represents the culmination of many years of significant investment in a next-generation platform and is a major step forward for Axion. We are extending our established leadership in MEA into high-definition electrophysiology and advanced spatial cell analysis. By bringing these capabilities together on a common platform, Synexus supports the applications our customers rely on today while creating new opportunities across emerging applications and markets.”
Designed for the next generation of live-cell research
As biotechnology research increasingly relies on complex human cell models and phenotypic assays, laboratories need technologies that can capture multiple dimensions of cellular biology without disrupting cells or sacrificing throughput.
Synexus was designed with this in mind; instead of operating as a fixed-purpose instrument, it lets researchers configure the system for today’s applications, then add measurement capabilities, analysis modules, plate formats, and workflows as their research evolves. This approach enables laboratories to protect their investment while giving Axion a common technology foundation for continued innovation.
Synexus brings together:
- High-throughput, label-free functional analysis, with simultaneous recording from up to 96 wells, with 384-well coming soon.
- Single-cell resolution, enabled by Pixel HD technology with more than 138,000 electrodes per well and 12.5 µm electrode spacing.
- Application-specific workflows, supported by purpose-built software and consumables for neural, cardiac, and other live-cell analysis applications.
Stacie Chvatal, vice president of Product Management at Axion BioSystems, said, “Synexus gives researchers a way to connect functional activity with morphological change, providing a more complete picture of cellular behaviour. By capturing both on the same plate, with the detail and throughput Synexus provides, researchers can uncover spatial heterogeneity and structure-function relationships that are difficult to see when measurements are separated across instruments or endpoints.”
Beyond MEA: Carrying a proven foundation into the next era of discovery
Synexus builds on Axion BioSystems’ experience and an established live-cell analysis ecosystem that includes over 1,500 systems installed worldwide and thousands of peer-reviewed publications using Axion technology. Its Maestro MEA technology has an established track record in pharmaceutical safety research, with widespread adoption among drug developers.
By extending this foundation into high-definition electrophysiology and electrical imaging, Synexus expands the possibilities for label-free, functional cell analysis across neuroscience, cardiac research, drug discovery, safety pharmacology, disease modelling, and other applications that depend on noninvasive, real-time measurements from living cells.
